Document is current
Any future updates will be listed below
-
Authors
Wipfli, F.
A. Lone, M. https://orcid.org/0000-0001-9710-775X
von Eckardstein, A.
Verrijken, A.
Francque, S.
Weyler, J.
Van Gaal, L.
Staels, B.
Hornemann, T.
-
Funding
Funding for this research was provided by:
University of Zurich
- License Information
-
More Information
Article History
Received: 22 August 2025
Accepted: 1 October 2025
First Online: 2 November 2025
Declarations
:
: S.F. has received grants from Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, Roche. He has acted as consultant for Abbvie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Alnylam, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristoll-Meyers Squibb, CSL Behring, Coherus, Echosens, Dr. Falk Pharma, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Genflow Biosciences, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, PRO.MED.CS Praha, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, Mursla Bio, NGM Bio, Novartis, Novo Nordisk, Promethera, Roche, Siemens Healthineers. SF has been lecturer for Abbvie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, Siemens.
: This study complies with the Declaration of Helsinki and was performed according to ethics committee approval. All participant have given a written informed consent. The study approval was granted by the Ethics Committee of the Antwerp University Hospital (reference 6/25/125, Belgian registration number B30020071389).
